Gastroenterology Associates of Central Georgia

Macon, Georgia 53226

4 studies enrolling now · 27 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Eosinophilic Esophagitis (EoE), Hepatitis C, Chronic, Inflammatory Bowel Disease, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Nonalcoholic Steatohepatitis

Studies at this site

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) — Stopped early
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Dietary Treatment of Crohn's Disease — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis — Completed
• New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis — Completed
• Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission — Completed
• Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study — Completed
• An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 — Completed
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease — Stopped early
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed